According to the latest study, the novel coronavirus, SARS-CoV-2, remains viable in aerosol form for several hours and on surfaces for several days. The data indicate that the stability of the new of the virus is similar to the stability of SARS-CoV-1. SARS-CoV-2, which causes COVID-19, quickly outpaced the pace of the 2003 SARS epidemic. The novel coronavirus appears to spread more through human-to-human transmission in a variety of settings.
However, it is not yet known to what extent asymptomatic or pre-symptomatic people are spreading the new virus in their daily lives.
Estet-portal.com will tell what conclusions the scientists came to:
- SARS-CoV-2 in the air and on surfaces
- COVID-19 statistics in the US and worldwide cases
- COVID-19 forecasts
- the pills that kill you are not the coronavirus
SARS-CoV-2 in the air and on surfaces
To find out how long SARS-CoV-2 remains infectious in the environment, PhD from the US Laboratory of Virology, Division of Internal Affairs, National Institute of Allergy and Infectious Diseases in Hamilton, and colleagues conducted simulation experiments in which they compared viability of SARS-CoV-2 with the viability of SARS-CoV-1 in the air and on surfaces.
Read also: How to distinguish coronavirus from colds and SARS
Researchers used nebulizers to create aerosols. Samples of SARS-CoV-1 and SARS-CoV-2 were collected at 0, 30, 60, 120 and 180 minutes on a gelatin filter. They then tested the infectivity of the viruses on specially grown Vero cells.
Subscribe to our page on Facebook!
They found that SARS-CoV-2 was largely stable throughout the full 180-minute test, with a slight decline after 3 hours. Both viruses have an average half-life in aerosols of 2.7 hours (range: 1.65 hours for SARS-CoV-1 and 7.24 hours for SARS-CoV-2).
The researchers then tested for viruses on a variety of surfaces for up to 7 days using humidity and temperature values designed to simulate "various domestic and hospital situations." The viral exposure volumes the team used were consistent with those found in the human upper and lower respiratory tract.
The novel coronavirus was most stable on plastic and stainless steel, with some viruses remaining viable for up to 72 hours. By that time, however, the viral load had fallen by about three orders of magnitude, indicating an exponential decline. This variant was remarkably similar to the SARS-CoV-1 variant, according to the authors.
However, the two viruses differed in strength on copper and cardboard.
No viable SARS-CoV-2 was detected on copper after 4 hours or on cardboard after 24 hours.
In contrast, SARS-CoV-1 was not viable after 8 hours on either copper or cardboard.
Read also: Coronavirus in the world. French view of the pandemic.
Combinedly, the results show that aerosol transmission of SARS-CoV-2 is plausible, as the virus can survive in the air for hours and on
A review of more than 4,000 patients in the US diagnosed with novel coronavirus infection (COVID-19) shows that an unexpected 20% of deaths occurred in adults aged 20-64 and 20% of those hospitalized were aged 20-44 years.
People over 65 were expected to be most vulnerable to infection
COVID-19, but this study shows that, at least in the United States, a significant number of patients under 45 years of age may be exposed to hospital and even die from this disease. To assess hospitalization and death rates among COVID-19 patients worldwide by age group, the Centers for Disease Control and Prevention analyzed 4,226 cases of COVID-19 worldwide that were reported between February 12 and March 27. Overall, older patients in this group were the most likely to be hospitalized with COVID-19. Similar to reports, this finding suggests that the risk of serious illness and death from COVID-19 is higher in older age groups.
People aged 19 yearsand younger have been statistically shown to have milder illness from COVID-19, with virtually no hospitalizations or deaths in this age group. But compared to the under-19 group, patients aged 20-44 appeared to be at higher risk of hospitalization according to the incidence report.
Read also:How to take antibiotics correctly
Of the 508 patients known to have been hospitalized, 9% were aged 85 years or older, 36% were aged 65-84 years, 17% were aged 55-64 years, 18% were aged 45-54 and 20% were in their 20s. -44 years. Among 121 patients admitted with acute respiratory infections, 7% were aged 85 years and older, 46% were aged 65-84 years, 36% were aged 45-64 years and 12% were aged 20-44 years. year.
Of the 44 deaths,
more than a third,were among adults aged 85 and over, 46% were among adults aged 65-84, and 20% were among adults aged aged 20-64. COVID-19 forecasts
Researchers believe more follow-up time is needed to determine outcomes among active patients. These results may also overestimate the prevalence of severe disease, as the initial approach to testing for COVID-19 targeted people with more severe disease.
Preliminary data also indicate that severe illness leading to hospitalization, including death, can occur in adults of any age with COVID-19. Speaking of forecasts, most likely the mortality statistics will not change, the same groups of people will remain at risk, given the fact that the
virus will not start to mutate. The pills that kill you, not the coronavirus
The
COVID-19virus enters the lung alveolar cell via the ECAII receptor. Contacting him, he kills the alveolar cell. Men have more receptors than women and people who take antihypertensive medications such as antiECA and in particular anti-ECAII have severe overexpression of the receptor, so they are more susceptible to infections. Read also:
Human papillomavirus, why vaccination is neededThose who took anti-inflammatory drugs in the early stages, such as Aspirin, Ibuprofen, Voltaren (diclofenac), etc., ended up in intensive care with bilateral pneumonia and severe consequences.
Ibuprofen (and similar anti-inflammatory drugs) cause a 5-fold increase in the virus!
It is only possible to take paracetamol on prescription and drink warm water with lemon every 15 minutes.
Information taken from reliable American sources:
https://www.medscape.com/viewarticle/927474YouTube